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Hepatitis  B virus  infection  (HBV)  is  a signiﬁcant  public  health  problem  in sub-Saharan  Africa.  Universal
infant  vaccination  with  the  hepatitis  B (HB)  vaccine  has  been  implemented  within  the  South  African
Expanded  Programme  of Immunization  since  April  1995  with  concomitant  reduction  in  HBV  infection  in
children.  However,  the  ﬁrst  vaccine  dose  is  only  administered  at six  weeks  of  age.  This  delay  may  lead  to
a failure  to  reduce  the risk  of  perinatal  HBV  transmission  to infants  born  to HIV/HBV  co-infected  women,
in  whom  HBV  infection  is often  upregulated.  The  aim  of  this  study  was to  determine  the  prevalence  of
HBV  infection  in babies  born  to  HIV-infected  mothers  in the  Western  Cape,  South  Africa.  HBV serological
markers  were  tested  in  all infant  serum  samples  and  following  HB  viral  load  testing,  sequencing  and
genotyping  were  also  performed.  Three  of  1000  samples  screened  tested  positive  for HBsAg  and  HBV
DNA.  An  additional  infant  tested  positive  for  HBV  DNA  alone.  All  babies  had  received  the HB vaccine  at  6,
10  and  14  weeks.  The  prevalence  of  HBV  infection  was therefore  4/1000  (0.4%;  95%  CI, 0.01–0.79%).  Three
of  four  infants  and all four  mothers  were  followed-up.  Two  infants  were  persistently  positive  for  HBsAg
with  viral  loads  above  108 International  Units  per millilitre.  All four maternal  samples  were  positive  for
HBsAg  and HBeAg  and  one  was  also  positive  for anti-HBe.  Sequencing  analysis  of two  mother–child  HBV
pairs  showed  100%  sequence  identity.  This study  demonstrates  HBV  infection  in HIV-exposed  infants
despite  HB  vaccination  from  6 weeks  of  age.  A more  strategic  approach  is  needed  to  prevent  mother  to
child  transmission  of  HBV,  including  screening  of  pregnant  women,  HBV-targeted  antiviral  therapy  and
HB  birth  dose  vaccine.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Hepatitis B virus infection (HBV), a signiﬁcant public health
roblem, is endemic in sub-Saharan Africa (SSA). The prevalence
ere is amongst the highest worldwide [1], with some regional dif-
erences. For example, in South Africa, HBsAg prevalence in adults
anges from 3% to 25%, with the highest rates in HIV-infected adults
1–6]. Antenatal data from Malawi and Zimbabwe report preva-
ences of 13% [7] and 25%, respectively [8].
SSA has more than 70% of the world’s HIV infections; includ-
ng 6.1 million HIV infected people in South Africa alone [9].
hronic HBV infection in the HIV-infected patient is an important
o-morbidity [10,11] with more rapid progression of cirrhosis [12],
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.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
higher hepatitis B (HB) viral loads [13,14] and a higher HBeAg
prevalence [13].
HBV infection is preventable. A safe and effective vaccine has
been available for over three decades. Remarkable success in reduc-
ing long-term complications in high prevalence areas, like Taiwan,
has been reported [15]. World Health Organisation guidelines advo-
cate that the ﬁrst dose of infant HB vaccine be administered in
the ﬁrst few days of life [16]. However, in most SSA countries,
the ﬁrst dose is administered at six weeks of age. This schedule
is based on epidemiological studies showing that African mothers
are predominantly HBeAg-negative, [17] therefore at low risk of
transmitting HBV vertically [18]. Studies conﬁrming this low risk
showed little to no early HBV infection in children, but increasing
acquisition between the ages of one and ﬁve years, suggestive of
horizontal transmission amongst siblings and playmates [18–22].
With HIV/HBV co-infection, HB viral load may  be high and HBeA-
gaemia more common. Therefore, delaying ﬁrst vaccination to six
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Demographics of laboratory and study populations.
Characteristic Laboratory
population*
(n = 2582)
Study
population
(n = 1000)
Age
Median, days (range) 45 (0–730) 46 (0–540)
Sex
Male, % 41.2 48.7
HIV status
HIV-infected, % (95% CI) 4.6 (3.3–5.9) 6.1 (4.62–7.58)N. Chotun et al. / Vac
eeks may  lead to a failure to reduce the risk of perinatal HBV trans-
ission to infants born to HIV/HBV co-infected women, in whom
BV infection is often upregulated [23]. The aim of this study was
o determine the prevalence of HBV infection in infants born to
IV-infected mothers in the Western Cape, South Africa.
. Materials and methods
.1. Study population
This was a cross-sectional study. EDTA plasma samples from
nfants between the ages of 0 and 18 months, whose mothers were
IV-infected, and whose samples were submitted for routine HIV-
 PCR testing to the Division of Medical Virology, National Health
aboratory Service (NHLS), Stellenbosch University, between June
011 and February 2012, were selected for this study. Samples with
ess than 100 l residual volume were excluded. Age, sex and HIV
tatus of all infants were documented. Ethics approval was  granted
y the Health Research Ethics Committee of Stellenbosch Uni-
ersity (Ethics Reference Number: N11/05/151). All samples were
ested for HBsAg. HBV DNA testing was performed in all samples
y pooling four samples per run as described previously [24]. The
imit of detection of this assay was 50 International Units per millil-
tre (IU/ml). All HBsAg or HBV DNA positive infants were traced
nd maternal and infant follow up samples underwent serological
nd molecular HBV testing. Additional demographic information
ncluding the ages of the mothers and children at follow-up, the
accination status of the children at follow-up and the CD4 counts
f the mothers at or around the time of delivery were collected.
.2. HBV serological testing
All samples were tested for HBsAg using the Murex HBsAg Ver-
ion 3 enzyme immunoassay (EIA) (Murex, Biotech Ltd., Dartfort,
K) according to manufacturer’s instructions. Positive results were
onﬁrmed using an in-house neutralisation assay performed with
he Murex HBsAg Version 3 EIA and 10 IU/ml anti-HBs (supplied by
he Blood Borne Viruses Unit, Public Health England, London, UK).
ll conﬁrmed HBsAg positive samples were tested for HBeAg and
nti-HBe by EIA using the ETI-EBK PLUS and ETI-EBK AB PLUS kits
rom Diasorin (Saluggia, Italy) respectively according to manufac-
urer’s instructions.
.3. HBV molecular testing
.3.1. HB viral load
DNA was extracted using the QIAamp® MinElute Virus Spin Kit
nd the presence of HBV DNA was detected by a real-time PCR
ssay [25]. The ﬁnal reaction volume was 25 l and the real-time
CR was performed on the RotorGeneTM 6000 (Corbett Life Science,
ustralia) using the following cycling parameters: an initial dena-
uration for 15 min  at 95 ◦C followed by 45 cycles of 95 ◦C for 15 s
nd 60 ◦C for 60 s.
.3.2. Sequencing
DNA positive samples were sequenced using primers target-
ng the pol/surface regions [26]. To determine the HBV genotype
nd identify any drug-resistance mutations in the HBV strains,
hese sequences were submitted online to HBVSeq (http://hivdb.
tanford.edu/HBV/HBVseq/development/HBVseq.html)..3.3. Phylogenetic analyses
A Maximum Likelihood phylogenetic tree based on the Kimura
-parameter model [27] with a bootstrap of 1000 replicates was
onstructed in MEGA 6 [28] using mother–child paired sequences,* Total number of samples received for HIV-1 PCR testing by the NHLS during the
sample collection period; CI: Conﬁdence Interval.
antenatal HBV sequences from the Western Cape [6] and additional
HBV sequences obtained from GenBank.
3. Results
3.1. Study population
From 2582 infant plasma specimens received from 203 Western
Cape clinics between June 2011 and February 2012 for HIV-1 PCR
testing (laboratory population), 1000 individual samples (39% of
the laboratory population) from 106 clinics comprised the study
population. Table 1 shows no signiﬁcant differences between the
demographics of the study and laboratory populations.
3.2. Screening tests results
Three of 1000 samples were reactive for HBsAg and conﬁrmed
positive by HBsAg neutralisation. All three samples were also pos-
itive for HBV DNA. One additional infant’s sample was positive
only for HBV DNA (Table 2). Since a very low level of HBV DNA
(<200 IU/ml) was detected in the plasma of this infant in the
absence of HBsAg, he was  considered to have an occult hepatitis
B virus infection (OBI). OBI is characterised by the persistence of
detectable HBV genomes in HBsAg negative individuals [29]. The
prevalence of HBV infection in this study cohort was therefore
4/1000 (0.4%; 95% conﬁdence interval (CI), 0.01–0.79%). None of
the four infants was  HIV-infected. They were all male.
3.3. Follow up
One of the four infected infants (the one with the occult infec-
tion) could not be traced (this infant was no longer in the care
of his mother); the remaining three HBsAg positive infants were
reviewed at a single follow up visit. The median infant age at follow-
up was  195 days (range 174 to 232 days). The mean age of the four
mothers was 29.5 years (range 26 to 35 years).
3.4. Follow up serological and molecular test results
All three infants had received three doses of the HB vaccine at
6 weeks, 10 weeks and 14 weeks, conﬁrmed by child vaccination
records. Two  were persistently positive for HBsAg and HBeAg. All
four samples from the mothers were conﬁrmed positive for HBsAg
and HBeAg. One mother’s sample was  also positive for anti-HBe.
Two  HBsAg positive infant samples were positive for HBV DNA,
with viral loads above 108 IU/ml. HBV DNA was not detected in the
third infant’s sample. All four mothers had detectable HBV DNA,
three of whom with HB viral loads greater than 108 IU/ml. The
fourth mother, who was  also anti-HBe positive, had an HB viral
load of 103 IU/ml (Table 2).
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Table 2
Serological and molecular results of four infected mother–child pairs at screening and follow-up.
Patient Screening Follow-up
HBsAg HBV DNA IU/ml HBsAg HBeAg HBV DNA IU/ml AntiHBe
MH1  ND ND + + 1 × 108 −
BH1  + 1 × 102 − ND UD −
MH2  ND ND + + 1 × 103 +
BH2  + 2 × 108 + + 6 × 108 −
MH3  ND ND + + 4 × 108 −
BH3  + 5 × 104 + + 2 × 109 −
MH4  ND ND + + 4 × 107 −
BH4* − 5 × 101 ND ND ND ND
* Patient was lost to follow-up; IU/ml: International Units per millilitre; HBsAg: hepat
B  e antigen; BH: Infected infant; MH:  Mother of infected infant; − Negative; + Positive; N
Fig. 1. Phylogenetic tree of mother–child pairs with HBV strains belonging to
subgenotype A1 based on pol/surface region. BH: Infected infant; MH: Mother of
infected infant; Sequences D001801, D002438, D002911 D002784 and D003920
were sequenced from patients from the Western Cape [6]. Sequences with acces-
sion numbers AY233290.1, AY233279.1, AY233287.1, AY903452.1, JN182327.1,
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therefore reduce HB viral loads and risks of vertical transmis-
sion [36,37]. The women  who transmitted HBV vertically had CD4
counts above 350 cells/mm3, so received neither tenofovir nor
Table 3
Age of HBV-infected infants at diagnosis.
Infant Age at diagnosis, days
BH1 53N182333.1 and GQ184326.1 were downloaded from GenBank. The evolutionary
istory was  inferred using the Maximum Likelihood method based on the Kimura
-parameter model [27]. There were a total of 917 positions in the ﬁnal dataset.
The HBV pol/surface regions from the two HBsAg positive infant
amples and four maternal samples were sequenced. All belonged
o subgenotype A1. No mutations associated with drug-resistance
r vaccine-escape were identiﬁed in the pol/surface regions. The
BV sequences from two mother–child pairs were used to con-
truct a phylogenetic tree (Fig. 1). The HBV sequences from the
wo mother–child pairs (MH2/BH2 and MH3/BH3) showed 100%
equence identity.
. Discussion
This study shows a prevalence of HBV infection of 0.4% in a
ohort of 1000 HIV-exposed infants. All four mothers who  trans-
itted HBV to their infants were HBeAg positive and were not on
ntiretroviral therapy (ART). Two of the three followed-up infants
emained persistently infected, with high HB viral loads at around
even months of age. These data suggest vertical transmission of
BV in these HIV-exposed infants, despite routine HB vaccination.
Several observations support a vertical route of transmission inhe four HBV-infected infants. First, all were below eight months
f age when HBsAg positivity was conﬁrmed (Table 3). At this
ge, exposure to other sources of infection is limited. Second, all
our mothers were HBeAg positive, a known risk factor for verticalitis B surface antigen; HBeAg: hepatitis B e antigen; AntiHBe: antibody to hepatitis
D: Not done; UD: Undetectable.
transmission. Although the HB viral load in one mother was
103 IU/ml at review, we  do not know what it had been at delivery.
It is possible that she was seroconverting in the early post-natal
period and may  have had a higher viral load during pregnancy.
Lastly, in the two  sequenced mother–child pairs, phylogenetic anal-
ysis showed that the strains were identical, supporting a maternal
source.
The HB vaccine was  introduced into South Africa almost two
decades ago, when the HBsAg prevalence in children was  approx-
imately 10% [30]. Subsequently, there has been a decrease in HBV
infections in children. In Limpopo, a northern province of South
Africa, HBsAg was found in 3 of 303 (0.9%) children between 5 and
24 months of age [31]. In an earlier study carried out in the same
province, none of 598 children had an HBV infection (HIV status
not reported). Only one mother in that cohort was HBeAg positive
[32]. Another cross-sectional study from South Africa comparing
pre- and post-vaccination cohorts over an almost 20 year period
showed a decrease in HBsAg prevalence from 4.2% to 1.4% [33].
HBeAg status of mothers is an important marker of HBV trans-
mission risk. HBeAg positivity was considered rare in pregnant
women in SSA [17]. However, we  have previously shown HBeAg
positivity in 18.9% of HIV-infected and 17.1% of HIV-uninfected
HBsAg positive women [6]. In HIV/HBV co-infected women  with
low CD4 counts, 42% (5/12) were HBeAg positive [23]. In a more
recent South African study, HBeAg prevalence was 43% and HBV
mother to child transmission rate was  28% in HIV/HBV co-infected
women [34]. In a Malawian study in HIV-infected women and their
HIV-exposed uninfected infants, of 5% of HBsAg positive women,
38% were also positive for HBeAg. In that study, the HBV transmis-
sion rate was  10%, with all infected infants born to HBeAg positive
women [35].
In the present study, with 0.4% of HIV-exposed infants being
HBV infected and a background HBsAg prevalence of 3.5% in
HIV-infected women  in the Western Cape [6,23], the HBV trans-
mission rate is similar to that reported elsewhere [35]. During
this study, HIV-infected pregnant women with CD4 counts below
350 cells/mm3 received ART, including tenofovir and lamivudine.
Tenofovir and lamivudine both have anti-HBV activity and wouldBH2 113
BH3 41
BH4 234
BH: Infected infant.
N. Chotun et al. / Vaccine 3
Table  4
Number of infants tested per age group.
Age, days Number of infants
0–1 7
2–4 8
5–10 7
11–20 35
21–30 14
31–42 199
43–70 451
71–98 115
99–180 64
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rural and institutionalized black children of Natal/KwaZulu South Africa. Int181–365 72
>365 28
amivudine. More recently, with the adoption of “Option B+” by
outh Africa in 2013, all HIV-infected pregnant women should now
eceive ART irrespective of their CD4 count. However, HIV infec-
ion is still being missed in pregnancy, with mothers therefore not
eceiving ART [38] and increasing the risk for both HIV and HBV
ransmission.
A birth dose of the HB vaccine reduces HBV vertical transmis-
ion from HBeAg-positive mothers by approximately 75% [39]. Data
rom SSA has shown the cost effectiveness of adding HB birth dose
accine [40]. Hepatitis B immunoglobulin (HBIG) has added ben-
ﬁt to prevent transmission [41]; however its cost and logistics
re prohibitive for most African settings. Mothers with high HB
iral loads (>105 IU/ml) are at risk of infecting their infants [42]
espite a birth dose of HB vaccine to neonates [43]. It is now well
stablished that treating these women during the late stages of
regnancy with nucleos(t)ides analogues will reduce the risk of
ransmission [36,37,44]. Although HBV-active ART is now available
o all HIV-infected pregnant women in South Africa, the infants of
BV monoinfected mothers remain vulnerable.
The results presented here should be interpreted in the context
f the study’s limitations. The small proportion of infants tested
or HBsAg before the age of one month in this cohort (7.1%) were
ll negative (Table 4). However, because of their young age, these
ould have been false-negative results and we may  therefore have
nderestimated the number of vertical transmissions in this cohort.
urthermore, the HB viral load of the mothers at delivery was
nknown. However, given that they were not on ART during preg-
ancy and were HBeAg positive, it is plausible that their viral loads
t delivery were high. In addition, this study only included the
nfants who attended clinic for HIV testing. Therefore our results
ay  have been biased against those infants whose mothers do not
egularly use health facilities such as antenatal clinics. As only HIV-
xposed infants were recruited, the results cannot be extrapolated
o HIV-unexposed children. Further work is required to investigate
he prevalence of HBV infection in HIV-unexposed infants.
. Conclusion
The addition of the HB vaccine to the South African Expanded
rogramme of Immunization has successfully decreased HBV infec-
ion prevalence from around 10% to around 1% in one to ﬁve year
lds in a period of two decades. However, HBV mother to child
ransmission is still occurring in HIV-exposed children, and reduc-
ng this to zero is possible. Screening for HBV during pregnancy,
ccess to HBV-targeted antiviral therapy and HB birth dose vaccine
re strategic and feasible approaches to achieving this.onﬂict of interest statement
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